What Drotaverine-Borimed treats: main uses and benefits

Drotaverine-Borimed is an antispasmodic medication containing drotaverine hydrochloride. It acts directly on smooth muscles to induce relaxation, which helps alleviate pain caused by involuntary muscle contractions. Unlike some other medications that affect the nervous system, drotaverine works directly on the muscle tissue, making it effective for various types of internal spasms.

Primary Indications

The medication is primarily used to manage spasms associated with diseases of the biliary tract and urinary system. Its muscle-relaxing properties are utilized in the following conditions:

• Biliary Spasms: It helps relieve pain related to gallbladder and bile duct issues, such as cholecystitis (inflammation of the gallbladder), cholangitis, and gallstone disease (cholecystolithiasis).
• Urinary Spasms: It is used for spasms of the urinary tract, including those caused by kidney stones (nephrolithiasis), bladder stones, and inflammation of the bladder (cystitis) or renal pelvis.

Secondary Uses

Drotaverine-Borimed may also be used as supportive therapy for smooth muscle spasms originating in the gastrointestinal tract and the reproductive system. These applications include:

• Gastrointestinal Conditions: Alleviation of spasms associated with gastric and duodenal ulcers, gastritis, and various forms of enteritis or colitis.
• Gynecological Conditions: Management of pain associated with menstrual cramps (dysmenorrhea).
• Tension Headaches: In certain cases, it may be used to reduce pain resulting from vascular or muscular tension in the head.

Benefits of Action

Drotaverine is characterized by its ability to act on smooth muscles without significantly affecting the autonomic nervous system. This direct mechanism allows for:

• Rapid Relaxation: The medication helps to quickly lower the tone of smooth muscles in internal organs.
• Vasodilation: It can promote increased blood flow to tissues by relaxing the smooth muscle walls of blood vessels.
• Broad Application: Because smooth muscle is present throughout the digestive, biliary, and urogenital systems, the medication is versatile in addressing localized cramping and colic.

Regulatory References

1. Swissmedic Public Assessment Report on Spaverin (Drotaverine)

Eligibility Map: Who Can and Cannot Use Drotaverine-Borimed

The use of Drotaverine-Borimed is strictly defined by regulatory guidelines focusing on the patient's underlying health status and age.

Contraindicated Populations (Must Not Use)

Use of this medicine is absolutely contraindicated in patients diagnosed with Severe Hepatic Insufficiency, Severe Renal Insufficiency, or Cardiac Insufficiency classified as Low Output Syndrome. It is also strictly prohibited for individuals with a known Hypersensitivity to the active substance, Drotaverine Hydrochloride, or to any of the tablet's excipients. Furthermore, due to excipient content, patients with rare hereditary conditions like Galactose Intolerance, LAPP Lactase Deficiency, or Glucose-Galactose Malabsorption must not use this medicine.

Age and Status Restrictions

The regulatory profile establishes use for Adults and Adolescents (age 12 and older). Use is restricted for children aged 6 to 12 years and is generally not recommended for children under 6 years, as no data are available for this younger age group. During Pregnancy, use requires special caution and is only advised when a medical professional determines the benefits outweigh the risks. The medicine is not recommended for women who are lactating (breastfeeding). Caution is also advised for Older Adults and patients with pre-existing Hypotension (low blood pressure).

Interactions with other medicines and products

The interaction profile for Drotaverine-Borimed is defined by specific pharmacodynamic reinforcement and pharmacokinetic alteration patterns documented in official regulatory labeling. This section describes the formally stated outcomes of combining the medicine with other products.

Co-administration with Levodopa is noted to reduce its antiparkinsonian effect, which can result in the worsening of symptoms such as rigidity and tremor. This constitutes a high-risk functional restriction documented in official labeling.

Pharmacodynamic Effects

The medicine demonstrates several pharmacodynamic reinforcement effects:

• Hypotension Enhancement: The risk of low blood pressure is officially stated to be enhanced when co-administered with Tricyclic Antidepressants, Quinidine, or Procainamide/Novocainamid.
• Spasmolytic Reinforcement: The spasmolytic effect is generally enhanced when co-administered with other antispasmodic agents.
• Antagonistic Effects: Drotaverine reduces the spasmogenic activity of Morphine.
• Synergistic Effect: Phenobarbital is noted to improve the reliability of spasm removal.

Exposure and Toxicity Risks

Official regulatory information documents interactions that alter drug exposure or toxicity:

Co-administered Substance	Documented Interaction Outcome
Magnesium Hydroxide	May increase the absorption of Drotaverine.
Lithium	Co-administration may lead to an increase in Lithium toxicity.

The official labels do not specify mandatory timing rules for dose separation nor do they explicitly document interaction patterns with food, alcohol, or herbal products.

How Drotaverine-Borimed Works

Drotaverine-Borimed is a musculotropic antispasmodic that acts directly on smooth muscle tissue, initiating a biochemical cascade that modulates the baseline contractility of the muscle cells. The primary mechanism involves the selective inhibition of Phosphodiesterase-4 ( PDE4), an enzyme present in high concentrations within smooth muscle systems.

This enzymatic inhibition prevents the hydrolysis of cyclic Adenosine Monophosphate ( cAMP), causing its intracellular concentration to rise. The elevated cAMP levels activate Protein Kinase A ( PKA), which then deactivates Myosin Light Chain Kinase ( MLCK) via phosphorylation. This molecular sequence interferes with the formation of actin-myosin cross-bridges, resulting in the direct spasmolysis of involuntary smooth muscle tissue.

This spasmolysis affects hollow organs (such as the gastrointestinal and urogenital tracts) and the muscle surrounding blood vessels. This effect is responsible for the overall modulation of the inherent contractility of the tissue and a mild decrease in peripheral vascular resistance. The mechanistic effect is primarily expressed in situations governed by excessive muscle tone and is functionally constrained when a mechanical obstruction is the primary cause.

Official Administration Guidelines

The usage of Drotaverine-Borimed, which contains drotaverine hydrochloride, is defined by guidelines concerning its route of administration, dosage, and scheduling. Standard protocols define a structured approach for its use, based on the approved dosage forms.

---

Dosing and Route of Administration

Instruction	Official Statement
Route of Administration	Approved for Oral administration (tablets) and Parenteral administration (Intramuscular or Intravenous injection) for acute care.
Adult Oral Daily Dose	The dose typically ranges from 120 mg to 240 mg, administered in 2 to 3 separate, divided doses. The maximum daily dose must not exceed 240 mg.
Parenteral Administration	Injections (40 mg to 80 mg) are generally given in acute clinical settings, with intravenous (IV) administration performed slowly.

---

Procedural and Population-Specific Rules

Instruction	Official Statement
Timing in Relation to Meals	Oral tablets may be taken with or without food.
Children's Dosing	Specific lower maximum daily doses are defined for children over six. For children between 6 and 12 years, the maximum daily dose is 80 mg (in 2 divided doses). For children above 12 years, the maximum daily dose is 160 mg (in 2 to 4 divided doses).
Missed Dose Rule	If a dose is missed, the patient should take the next dose as scheduled; a double dose should be avoided to compensate.
Duration of Use	The medicine is generally intended for short-term symptomatic treatment.

---

These instructions establish the protocol for administering the medicine, distinguishing between the oral route for general, non-severe use and the parenteral route for managing acute situations. The specified dosing ranges and frequency patterns ensure the drug is taken multiple times per day to maintain its necessary levels, while mandatory age-specific limits define the maximum permissible dose for pediatric populations.

The clinical research for Drotaverine-Borimed (Drotaverine Hydrochloride) primarily focuses on its role in exploring acute or episodic physical discomfort linked to involuntary smooth muscle contractions, or spasms. This overview describes the structure of the available evidence without offering clinical recommendations.

---

Evidence for Use in Gastrointestinal Spasms

Research for this medication was evaluated in studies exploring conditions characterized by fluctuating or episodic manifestations, such as acute cramping or symptoms in patients with Irritable Bowel Syndrome (IBS). These studies, including both short-term Randomized Controlled Trials (RCTs) and observational settings, research examined patient-reported outcomes describing perceived discomfort and symptom variability. However, follow-up durations were limited in many studies, meaning there is limited information for long-term outcomes for chronic conditions like IBS.

---

Evidence for Use in Organ Colic and Dysmenorrhea

Research examined conditions associated with acute or disruptive episodes, specifically colic related to the kidneys (renal colic) and biliary system, as well as painful menstruation (dysmenorrhea). These studies were structured as acute-phase observation trials conducted during periods of heightened symptom activity. Trials described patterns related to pain level changes and the requirement for additional analgesic intervention was monitored over short time intervals.

---

Research Gaps and Limitations

The research mainly includes adults as the primary populations studied. Data for certain groups remain insufficient, particularly for children, the elderly, or pregnant individuals. While studies may include a range of disease severity, the results apply only to the populations studied, meaning subgroup findings are uncertain. Overall, the evidence highlights what is known for acute changes but indicates that research is ongoing and questions about long-term use and outcomes in diverse populations remain.

Key Studies & References

1. Antispasmodic Agents: General Pharmacological Class and Use
2. Swissmedic Public Assessment Report on Spaverin (Drotaverine)
3. Guidelines for the Management of Irritable Bowel Syndrome (IBS): Symptomatic Treatment

Common questions about Drotaverine-Borimed (FAQ)

Q: How quickly can a person generally expect Drotaverine-Borimed to start working?

Based on official pharmacokinetics data, the medicine typically reaches its highest concentration in the blood within about 1.9 hours after an oral dose. This measurement, known as Tmax, provides an indication of when the medicine’s maximum effect is likely strongest. It is important to remember that the feeling of relief may vary from person to person.

Q: How long does the overall relaxing effect of Drotaverine-Borimed typically last in the body?

Drotaverine-Borimed is intended for short-term, symptomatic treatment of spasms. Official data indicates that the medicine's elimination half-life—the time it takes for half the drug to be removed from the body—is generally in the range of 8 to 10 hours.

Q: Does Drotaverine-Borimed interact with over-the-counter pain relievers like paracetamol (acetaminophen)?

Official regulatory documents do not commonly list a specific interaction between single-ingredient Drotaverine and Paracetamol (Acetaminophen) that would cause increased toxicity. However, some combination products regulated in various regions contain both active ingredients to achieve a synergistic effect. This information highlights the importance of consulting a health professional regarding the co-administration of any medications.

Q: Is it described in official sources if Drotaverine-Borimed can interact with alcohol?

Official safety advice generally recommends avoiding alcohol consumption while taking this medicine. This caution is typically advised because alcohol consumption may increase the chance of experiencing certain side effects of the medication, such as dizziness or low blood pressure.

Q: What does it mean that Drotaverine-Borimed is structurally related to Papaverine?

Drotaverine is a benzylisoquinoline derivative, meaning it shares a similar chemical structure with Papaverine. Both are pharmacological antispasmodic agents used to relax smooth muscle. Official pharmacological descriptions note that Drotaverine has a more potent and selective mechanism by inhibiting the PDE4 enzyme compared to Papaverine.

Q: Can Drotaverine-Borimed influence a person's ability to drive or operate machinery?

Official regulatory documents advise caution regarding driving or operating machinery. This warning is based on the possibility of certain side effects, such as dizziness, headache, or low blood pressure (hypotension). The regulatory guidance advises avoiding activities requiring focus and coordination if these effects are experienced.

Q: Are there high-level descriptions of how Drotaverine-Borimed affects the nervous system?

The drug's primary action is targeted at the smooth muscle tissue of the body's internal organs, not the central nervous system. However, official regulatory information classifies common side effects like headache, dizziness, and insomnia under 'Nervous System Disorders.' These effects represent how the body's nervous system can be indirectly affected.

Q: What are the possible signs or symptoms of taking too much Drotaverine-Borimed (overdose)?

Information concerning overdose symptoms in humans is limited according to official safety reports. Potential severe effects may include cardiac rhythm and conduction disorders. In rare, very severe cases, cardiac arrest has been reported. Suspected overdose requires immediate assessment by a qualified health professional.

Q: Does official information suggest Drotaverine-Borimed is safe to use if a person is allergic to similar medications?

Official information absolutely contraindicates use if a person has a known hypersensitivity to Drotaverine Hydrochloride itself or to any of the tablet's non-active ingredients. While the drug's mechanism is distinct from other antispasmodic classes, official regulatory documents do not universally provide specific cross-allergy information for all other 'similar' medications.

Q: How does the drug work to relieve spasms without causing certain side effects often seen with anticholinergics?

This drug is a PDE4 inhibitor, which is a non-anticholinergic mechanism. Drotaverine is noted not to act on muscarinic receptors, which is the site of action for classical anticholinergic antispasmodics. This difference in action means it typically does not produce the strong anticholinergic side effects, such as severe dry mouth or urinary retention, seen with that drug class.

Q: Is it true that Drotaverine-Borimed may be used to help with cervical spasms during labor, according to research?

Research has investigated Drotaverine for obstetric applications, specifically its potential role in managing cervical dilation during labor. However, official regulatory documents often state a general precaution or non-recommendation for use during pregnancy. The medicine is generally reserved for use only when a health professional determines the benefits are supported by the medical situation.

Q: Are there reports in research literature about Drotaverine being used for conditions like benign prostatic hyperplasia (BPH)?

Research literature has noted that Drotaverine has been investigated for certain non-spasmodic conditions, including benign prostatic hyperplasia (BPH). It is important to note that BPH is not an approved therapeutic indication for this medicine according to its official labeling.

Q: What is the difference between Drotaverine and the common drug Dicyclomine?

Official pharmacological classification identifies Drotaverine as a selective PDE4 inhibitor, placing it in a non-anticholinergic class of antispasmodics. In contrast, Dicyclomine (Dicycloverine) functions as an anticholinergic antispasmodic. This fundamental difference in mechanism results in distinct action profiles and potential side effect profiles.

Storage and Disposal of Drotaverine

Drotaverine tablets must be stored according to mandatory conditions outlined in official regulatory labeling to ensure product stability.

---

Storage Requirements

Condition	Requirement
Temperature	Do not store above 30 C.
Protection	Store in the original package to protect from light and moisture.
Container	Blisters must be kept in the outer carton until use.
Safety	Keep out of the reach and sight of children.
Stability	Do not use the product after the expiry date (EXP) printed on the pack.

---

Disposal Instructions

Any unused or expired medicinal product or waste material must be disposed of in accordance with local regulations for pharmaceutical waste. The product should not be discarded via household waste unless specifically authorized by local guidance.